Obesity has become a pandemic, affecting both children and adults. We sought to determine the effect of obesity among 200 children who were prospectively enrolled on a multicenter cord blood transplant (CBT) trial. All patients received myeloablative preparative regimens. Children were classified into groups according to body mass index percentile. Normal weight was defined as body mass index between the 5th and 85th percentile (n ¼ 117), overweight between the 85th and 95th percentile (n ¼ 35) and obesity above 95th percentile (n ¼ 39) for age and gender. A total of 55 patients (27%) had AML, 113 patients (57%) had ALL and 32 patients (16%) had other malignant diseases. There was no evidence for a difference in all major characteristics among the groups. Time to neutrophil and platelet engraftment, TRM, risk of acute GVHD, diseasefree survival and OS were not significantly different in overweight or obese patients compared with normal weight patients. There was a trend towards increased risk of chronic GVHD in obese patients (P ¼ 0.05) compared with normal weight patients. In conclusion, there is insufficient evidence from this sample that obesity has an effect on multiple outcomes after unrelated CBT in children with malignant diseases.
Introduction
Obesity has become a pandemic in the US, affecting both children and adults. According to the National Health and Nutrition Examination Survey (NHANES), data from [2003] [2004] [2005] [2006] report that 31.9% of children aged 2-19 years are classified as being overweight or obese. 1 This is in comparison with adult data, in which the NHANES from 2003-2004 reported 32% of adults are overweight and 34% are obese. 2 Evidence continues to emerge regarding the health complications of obesity, including the detrimental effects obesity has on the treatment of malignant diseases. Several studies demonstrate conflicting results on the effect obesity has on the outcome of SCT in adult patients. Although some have reported that obesity increases the risk of TRM in adult patients receiving auto-or allo-SCT, others have failed to show any effect on major outcomes. [3] [4] [5] [6] Limitations of prior studies include retrospective analyses, small numbers of patients and non-uniform dose adjustments for obese patients.
Compared with adults, less is known about the implications obesity has on survival in children receiving chemotherapy or undergoing SCT. In a Children's Cancer Group study, overweight children with AML had increased TRM and worse OS, as compared with those with a normal weight. 7 A single-center retrospective study has demonstrated inferior outcomes for overweight children undergoing allo-SCT. 8 To our knowledge, no data exist on the effect obesity has on key prognostic indicators in children undergoing unrelated cord blood transplants (CBT) for malignant diseases. To investigate the impact obesity has on children undergoing hematopoietic SCT, data from the CBT (COBLT) study were analyzed.
Methods
The COBLT study is a multi-institutional trial of CBTs sponsored by the National Heart, Lung and Blood Institute (NHLBI) branch of the National Institutes of Health. A total of 364 adults and children were prospectively enrolled in the study between 1999 and 2003. The protocol was approved by the institutional review boards (IRB) of all participating centers. Data from the study were made available by the NHLBI for analysis by a limited data agreement with Vanderbilt University. The analysis was approved by the IRB of Vanderbilt University Medical Center. A total of 200 patients p18 years of age who lacked HLA-matched related donors with malignant diseases were enrolled. Only subjects receiving one cord blood unit were eligible. Searches for cord blood unit were conducted by using low/intermediate resolution molecular typing for HLA class I (A and B) and high-resolution molecular typing for HLA DRB1. Selection of the unit was based on providing the highest number of total nucleated cell count (TNC) and matching at a minimum of 4/6 HLA loci. Data were analyzed retrospectively to determine the body mass index of each patient, as the study was not originally designed to evaluate the impact of obesity on outcome of hematopoietic SCT.
Transplant procedure
Conditioning regimens consisted of TBI, CY and antithymocyte globulin for patients with malignant diseases. One stratum evaluated the safety of BU, melphalan and antithymocyte globulin in young patients and those who were not able to tolerate TBI. The details of these preparative regimens have been previously reported. [9] [10] [11] For patients who were X125% ideal body weight, chemotherapy dosing was based on 40% adjusted ideal body weight based on the following formula: (actual weightÀideal body weight) Â 0.4 þ ideal body weight. GVHD prophylaxis consisted of methylprednisolone 0.5 mg/kg twice daily on days þ 1 through to þ 4 and then 1 mg/kg twice daily from days þ 5 to þ 19 or until the first day the ANC reached 500 cells/ ml, at which time the dose was tapered at the rate of 0.2 mg/ kg per week. CYA was started on day À3 and continued until at least day 180. CYA doses were based on actual body weight and it was recommended to adjust doses to keep trough levels of 200 ng per 100 ml. The dose was then tapered at the rate of 5% of the initial dose per week, if the recipient had no evidence of GVHD.
Definitions
Neutrophil engraftment was defined as achieving an ANC of at least 500 cells/ml for three consecutive measurements on different days and demonstrating donor chimerism of 490%. Platelet engraftment was defined as achieving a platelet count above 50 000 cells/mm 3 for three consecutive measurements on different days and not requiring platelet transfusions for a minimum of 7 days. The grading of acute GVHD followed the GVHD consensus grading scheme. 12 An algorithm calculated the maximum GVHD clinical grade on the basis of the weekly organ staging in skin, upper and lower gastrointestinal tract, and liver. This calculated organ stage was decreased by one stage if a listed specific differential diagnosis was reported for either gastrointestinal tract or liver. An independent panel reviewed all weekly records and assigned each patient a final maximum grade, similar to the methods described by Weisdorf et al. 12 Children were classified into groups according to BMI percentile, where normal weight is between the 5th and 85th percentile, overweight is between the 85th and 95th percentile, obesity is above the 95th percentile and underweight is less than the 5th percentile for age and gender according to the Center for Disease Control and Prevention (CDC) guidelines. 13 
Statistical analyses
Participants eligible for analysis were pediatric patients (aging from 2 to 18 years old) who had malignant disease. Accrued follow-up time began on the date when participants underwent CBT and ended on the date that participants experienced an event or end of study, whichever happened first. We used the Cox proportional hazards model to assess the association between obesity and OS, and the association between obesity and diseasefree survival (DFS), while controlling for multiple risk factors that have been shown to influence the outcome. We used regression modeling of sub-distribution functions in competing risks to assess the association between obesity and other outcome variables, including TRM, neutrophil engraftment, platelet recovery, acute GVHD and chronic GVHD, while controlling for other risk factors and considering death as the competing event. All models included obesity status (underweight, normal, overweight and obese), age, performance status, total cell count, CMV status, gender and HLA match. All statistical analyses were performed using R software (version 1.10.0, Vienna, Austria).
Results
There were 200 patients with a median age of 7.8 years (range 2.07-17.90) who were included in this analysis. Out of which, 55 patients (28%) had AML, 113 patients (57%) had acute ALL and 32 patients (16%) had other malignant diseases. The median TNC dose per kg infused was 5.2 Â 10 7 cells/kg (range 1.5-80.95 Â 10 7 cells/kg) and 74 patients (37%) received a HLA-matched or single antigen mismatch cord blood.
The median follow-up of surviving patients is 27 months (range 9-64). A total of 117 patients were of normal weight, whereas 35 were overweight, 39 were obese and 9 were underweight. The four groups were comparable with respect to gender, race, performance status, TNC dose per kg infused, conditioning regimen, degree of graft mismatch and CMV status. Obese patients were significantly younger than the other groups (P ¼ 0.002), ( Table 1) .
The cumulative incidence of neutrophil engraftment by day 42 was 73% (95% CI, 66-79). In a multivariable analysis, neutrophil engraftment was associated with a higher TNC dose (P ¼ 0.004). The cumulative incidence of platelet engraftment by day 100 was 35% (95% CI, 28-41) and higher in the male recipients compared with female recipients (P ¼ 0.029).
The cumulative incidence of grade II-IV acute GVHD and grade III-IV acute GVHD by day 100 was 49% (95% CI, 42-56) and 37% (95% CI, 30-43), respectively. There was some evidence for increased risk of grade III-IV acute GVHD for female patients (P ¼ 0.056). The cumulative incidence of chronic GVHD by 6 months was 6% (95% CI, 2-10). Patients who receive a higher TNC dose are more likely to develop chronic GVHD (P ¼ 0.001). There was a trend for increased risk of chronic GVHD for older and obese patients (P ¼ 0.054 and P ¼ 0.050).
The cumulative incidence of TRM by 1-year post transplant was 31% (95% CI, 24-37). There was a trend for increased TRM in female recipients (P ¼ 0.061). The probability of DFS and OS at 1 year was 51% (95% CI, 44-58) and 56% (95% CI, 50-64), respectively. Both DFS (P ¼ 0.002) and OS (P ¼ 0.001) were significantly worse among female recipients. Recipients who were CMV seropositive had significantly worse DFS (P ¼ 0.043) and a trend for worse OS (P ¼ 0.06).
There was insufficient evidence for increased TRM, or worse DFS and OS in patients who were underweight, overweight, or obese compared with normal weight children ( Table 2) .
Discussion
To our knowledge, this is the first study to report on the effect of obesity on outcomes following unrelated CBT. In our study, obesity did not adversely affect the OS or TRM. Our results are in contrast with a large retrospective singlecenter study examining the effect of obesity in 325 pediatric patients receiving an allo-SCT. 8 In that study, half of the patients received a related donor transplant, and only seven patients received cord blood as the stem cell source. This analysis revealed a worse survival among the obese patients. The major limitation of this study is the various approaches to chemotherapy dose adjustment, different donor sources and inclusion of patients with non-malignant diseases. We excluded patients with non-malignant diseases from our study because of the effect of the underlying metabolic or immune deficiency disorders on the weight of the patients. In a recent analysis by the Center for International Bone Marrow Transplant Registry (CIBMTR), overweight children with severe aplastic anemia undergoing SCT had significantly worse OS.
14 In this particular analysis, patients received various preparative regimens and donor sources. None of the patients in that study received an unrelated CBT.
There is limited and conflicting data regarding the effect of obesity on adult recipients of hematopoietic SCT. In adult patients receiving auto-, or allo-SCT for AML, Navarro et al.
15 reported no effect of obesity on OS, whereas patients who were underweight experienced worse survival following related donor transplant. In contrast with the prior study Meloni et al. 16 reported significantly worse survival in obese patients receiving auto-SCT. The authors did not have information regarding dose adjustments or the effect of obesity on the cell dose administered in this report. Similarly, obesity was not found to adversely affect the outcome of patients with lymphoma undergoing auto-SCT. 17 There are several reports describing the effect of obesity on the outcome following allo-SCT. In a large analysis carried out in the Fred Hutchinson Cancer Research Center, obesity did not affect the TRM and OS. 3 This is in contrast with data from the same center showing that body weight index (actual body weight divided by ideal body weight) adversely affected the outcome of patients undergoing unrelated donor transplant for CML. 18 A casecontrolled study from a single center that included 80 patients, who were younger than 16 years of age, demonstrated a worse OS among adult patients who were Table 1 Patient characteristics Effect of obesity in cord blood transplant M Pine et al obese but failed to show a difference among the pediatric patients. 4 Analysis from the Japan Marrow Donor Program, including more than 3000 patients, with various hematological malignancies did not show an adverse effect of obesity on TRM or OS. 5 That same study showed an increased risk of infection and increased risk of grade II-IV acute GVHD in obese patients. In our current study, we failed to find an association between acute GVHD and obesity, but there was a trend towards increased risk of chronic GVHD in these patients. The reason for this correlation between chronic GVHD and obesity in our analysis is not clear. This could be related to a difference in the metabolism of immunosuppressive medications in this patient population.
Characteristics of patients
The main limitations of prior published reports are their retrospective nature and the lack of consistent approaches to adjusting chemotherapy dosing for overweight and obese patients. In our analysis, the dose was adjusted in a uniform way for patients who were X125% ideal body weight. An additional factor that might potentially affect outcome following allo-SCT is the cell dose delivered. Higher cell doses have been associated with improved survival of recipients of unrelated marrow and CBT. 19, 20 Several of the prior studies did not include the cell dose in the statistical model. 4, 8, [14] [15] [16] For recipients of CBTs, the cord units are selected based on a minimum required cell dose per kg of actual body weight, thus eliminating the effect that cell dose might have for patients who are overweight. In our study, the median cell dose delivered was not significantly different between the patients who were overweight or obese and those who were normal weight. This might be the main reason why obesity did not affect neutrophil or platelet engraftment.
The effect of being underweight on outcome following SCT is not well known. In a recent study underweight adult patients with AML had significantly worse OS following related donor transplant compared with normal weight patients. 15 Although our study did not show an effect of being underweight on major outcomes, it is limited by the small number of patients who were underweight. Larger studies of children receiving CBT are needed to better understand the effect of being underweight on major outcomes. Effect of obesity in cord blood transplant M Pine et al
In conclusion, there is no evidence that obesity precludes safe and effective myeloablative unrelated CBT in children with hematological malignancies. Additional prospective studies with larger number of patients should be performed to better study the correlation between obesity and chronic GVHD in this population.
